Why is Syncom Formulations (India) Ltd falling/rising?

Recent Price Movement and Market Performance

Syncom Formulations hit a new 52-week low of ₹10.21 on the day, underscoring the persistent weakness in its share price. The stock has been on a consecutive two-day losing streak, registering a cumulative decline of 10.9% during this period. This recent underperformance is sharper than the sector average, with the stock lagging by 4.41% relative to its peers on the same day.

Examining the stock’s returns against the broader market reveals a concerning trend. Over the past week, Syncom Formulations has declined by 8.36%, significantly underperforming the Sensex’s modest 1.03% fall. The one-month and year-to-date figures further highlight the stock’s struggles, with losses of 16.19% and 27.82% respectively, compared to the Sensex’s declines of 10.33% and 15.57% over the same periods. The disparity widens over the one-year horizon, where the stock has plummeted 37.39%, while the Sensex has only fallen 7.06%.

Technical Indicators and Investor Activity

From a technical standpoint, Syncom Formulations is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning typically signals a bearish trend and suggests that short-term and long-term investor sentiment remains weak. The stock’s inability to sustain levels above these averages indicates persistent selling pressure.

Interestingly, despite the price decline, investor participation has increased notably. Delivery volume surged to 24.2 lakh shares on 27 March, marking a 116.58% rise compared to the five-day average delivery volume. This heightened activity could reflect increased trading interest, possibly from investors repositioning their portfolios amid the stock’s recent volatility. However, the increased volume has not translated into price support, as the stock continues to slide.

Liquidity remains adequate for trading, with the stock’s average traded value supporting trade sizes of approximately ₹0.05 crore based on 2% of the five-day average traded value. This ensures that investors can transact without significant market impact, although the prevailing sentiment remains negative.

Long-Term Performance Context

While the recent performance has been disappointing, it is worth noting that Syncom Formulations has delivered strong returns over the longer term. The stock has appreciated by 72.24% over three years and an impressive 232.26% over five years, substantially outperforming the Sensex’s respective gains of 24.13% and 43.50%. This contrast highlights the cyclical nature of the stock and suggests that current weakness may be part of a broader correction phase rather than a fundamental breakdown.

Nevertheless, the sharp underperformance relative to the benchmark and sector in the short to medium term, combined with the technical indicators and new 52-week lows, points to a cautious outlook for investors. The stock’s recent trajectory suggests that market participants are pricing in near-term challenges or uncertainties affecting Syncom Formulations.

Conclusion

In summary, Syncom Formulations (India) Ltd’s share price decline on 30 March is driven by a combination of sustained underperformance against the Sensex and sector peers, technical weakness evidenced by trading below all major moving averages, and a fresh 52-week low. Despite increased investor participation, the stock continues to face selling pressure, reflecting a cautious market stance. While the company’s long-term track record remains robust, the current environment signals a challenging phase for the stock, warranting careful consideration by investors.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →